Pegvisomant in acromegaly: a multicenter real-life study in Argentina

ABSTRACT Objective To describe the long term safety and efficacy of pegvisomant (PEGV), and the predictors of treatment response in patients with acromegaly in the real life setting. Subjects and methods We retrospectively reviewed the clinical, hormonal and radiological data of acromegalic pati...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Natalia Ximena Garcia Basavilbaso, Maria Carolina Ballarino, Darío Bruera, Oscar D. Bruno, Alberto B. Chervin, Karina Danilowicz, Patricia Fainstein-Day, Silvina Gabriela Fidalgo, Adriana Frigeri, Mariela Glerean, Rodolfo Guelman, Gabriel Isaac, Debora Adela Katz, Pablo Knoblovits, Fabiana Librandi, Monica López Montes, Maria Susana Mallea-Gil, Marcos Manavela, Paula Mereshian, Daniel Moncet, Analia Pignatta, Amelia Rogozinsky, Laura R. Sago, Marisa Servidio, Monica Spezzi, Graciela Stalldecker, Julieta Tkatch, Nicolas Marcelo Vitale, Mirtha Guitelman
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Sociedade Brasileira de Endocrinologia e Metabologia
Cyfres:	Archives of Endocrinology and Metabolism
Pynciau:	Pegvisomant acromegaly GH receptor antagonist clinical trial
Mynediad Ar-lein:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972019000700320&lng=en&tlng=en
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!